Data on AstraZeneca vaccine insufficient for Swiss approval
Last week Swissmedic received a large package of data from the pharmaceutical company, which it is now reviewing.
Copyright 2021 The Associated Press. All Rights Reserved
This content was published on
2 minutes
Keystone-SDA/gw
Español
es
Los datos de AstraZeneca son insuficientes para aprobación en Suiza
The medicines regulator Swissmedic says it has not yet received enough robust data from clinical trials to give the green light to the Covid-19 vaccine developed by the Swedish-British company.
While the supervisory authority saw conclusive results from studies involving many participants to approve two other coronavirus vaccines, the same could not be said for the Oxford-AstraZeneca shot, Swissmedic director Raimund Bruhin told the CH Media group of newspapers on Thursday.
But this did not mean that he believes the vaccine is a poor one.
“We are only saying that the company has not yet been able to prove to us that it is a good vaccine,” said Bruhin.
The approvals process, he added, was about hard data and facts. Last week Swissmedic received a large package of data from the pharmaceutical company, which it is now reviewing, and remains in regular contact with the makers of the vaccine.
Other countries, such as the United Kingdom, have been administering the AstraZeneca vaccine for over three months – although several nations have halted vaccinations in recent days over isolated cases of blood-clotting. The European Medicines Agency has said the benefits of the Oxford-AstraZeneca jab greatly outweigh the risks and on Thursday will issue a report on its investigation into cases of blood clots.
Switzerland has ordered more than 35 million doses of Covid-19 vaccines from five manufacturers. To date Swissmedic has approved shots developed by Pfizer/BioNTech and Moderna. Roughly 4% of the population has been vaccinated so far, but delays in approval and delivery have slowed the roll-out process.
Nature magazine: scientific breakthroughs in medicine and space travel in 2025
This content was published on
The science magazine Nature expects breakthroughs in mind-reading machines, new weight-loss drugs, and particle physics in 2025.
This content was published on
Swiss minister Karin Keller-Sutter wants to use Platform X to communicate with the population during her term as president in 2025.
Swiss Post delivers record number of parcels in pre-Christmas period
This content was published on
Swiss Post delivered a total of 22.3 million parcels between the Black Friday promotional week at the end of November and Christmas.
SWISS plane in Graz: employee still in intensive care
This content was published on
The cabin crew member of the SWISS Airbus A220 which made an emergency landing in Graz, Austria, on Monday is still in intensive care.
WWF sounds alarm: wildlife populations are plummeting
This content was published on
The WWF’s Living Planet Report 2024 found that the wild animal populations surveyed have shrunk by an average of 73% over the last 50 years.
Two decades after tsunami, Swiss tourists flock to Southeast Asia
This content was published on
Twenty years after a catastrophic tsunami in Southeast Asia, the region is again a top destination for Swiss, including at Christmas.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland could sell or give away AstraZeneca doses if regulator dithers
This content was published on
A lack of green light from medicines regulator Swissmedic could see 5.3 million doses ordered by Switzerland sent elsewhere.
This content was published on
Media reports indicate that vaccinating everyone who wants to by summer relies on meeting ambitious vaccine delivery targets in spring.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.